169 related articles for article (PubMed ID: 11950553)
1. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor.
Maes M; Bocchio Chiavetto L; Bignotti S; Battisa Tura GJ; Pioli R; Boin F; Kenis G; Bosmans E; de Jongh R; Altamura CA
Schizophr Res; 2002 Apr; 54(3):281-91. PubMed ID: 11950553
[TBL] [Abstract][Full Text] [Related]
2. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics.
Maes M; Bocchio Chiavetto L; Bignotti S; Battisa Tura G; Pioli R; Boin F; Kenis G; Bosmans E; de Jongh R; Lin A; Racagni G; Altamura CA
Eur Neuropsychopharmacol; 2000 Mar; 10(2):119-24. PubMed ID: 10706993
[TBL] [Abstract][Full Text] [Related]
3. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs.
Maes M; Bosmans E; Ranjan R; Vandoolaeghe E; Meltzer HY; De Ley M; Berghmans R; Stans G; Desnyder R
Schizophr Res; 1996 Jul; 21(1):39-50. PubMed ID: 8998275
[TBL] [Abstract][Full Text] [Related]
4. In vivo immunomodulatory effects of clozapine in schizophrenia.
Maes M; Bosmans E; Kenis G; De Jong R; Smith RS; Meltzer HY
Schizophr Res; 1997 Aug; 26(2-3):221-5. PubMed ID: 9323354
[TBL] [Abstract][Full Text] [Related]
5. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment.
Erbağci AB; Herken H; Köylüoglu O; Yilmaz N; Tarakçioglu M
Mediators Inflamm; 2001 Jun; 10(3):109-15. PubMed ID: 11545247
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice.
Sugino H; Futamura T; Mitsumoto Y; Maeda K; Marunaka Y
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):303-7. PubMed ID: 19138716
[TBL] [Abstract][Full Text] [Related]
7. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Zhang XY; Zhou DF; Cao LY; Zhang PY; Wu GY; Shen YC
J Clin Psychiatry; 2004 Jul; 65(7):940-7. PubMed ID: 15291683
[TBL] [Abstract][Full Text] [Related]
8. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine.
Maes M; Meltzer HY; Bosmans E
Acta Psychiatr Scand; 1994 May; 89(5):346-51. PubMed ID: 8067274
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers.
Maes M; Bosmans E; Calabrese J; Smith R; Meltzer HY
J Psychiatr Res; 1995; 29(2):141-52. PubMed ID: 7666381
[TBL] [Abstract][Full Text] [Related]
10. Serum TNF-α, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine.
Ajami A; Abedian F; Hamzeh Hosseini S; Akbarian E; Alizadeh-Navaei R; Taghipour M
Iran J Immunol; 2014 Sep; 11(3):200-9. PubMed ID: 25265997
[TBL] [Abstract][Full Text] [Related]
11. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics.
Grillo RW; Ottoni GL; Leke R; Souza DO; Portela LV; Lara DR
J Psychiatr Res; 2007; 41(1-2):31-5. PubMed ID: 16546213
[TBL] [Abstract][Full Text] [Related]
12. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
13. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?
DeQuardo JR; Tandon R
J Psychiatr Res; 1998; 32(3-4):229-42. PubMed ID: 9793876
[TBL] [Abstract][Full Text] [Related]
14. Blood biogenic amines during clozapine treatment of early-onset schizophrenia.
Schulz E; Fleischhaker C; Clement HW; Remschmidt H
J Neural Transm (Vienna); 1997; 104(10):1077-89. PubMed ID: 9503259
[TBL] [Abstract][Full Text] [Related]
15. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders.
Igue R; Potvin S; Bah R; Stip E; Bouchard RH; Lipp O; Gendron A; Kouassi E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1695-8. PubMed ID: 21627977
[TBL] [Abstract][Full Text] [Related]
16. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics.
Qi LY; Xiu MH; Chen DC; Wang F; Kosten TA; Kosten TR; Zhang XY
Neurosci Lett; 2009 Sep; 462(2):113-7. PubMed ID: 19539717
[TBL] [Abstract][Full Text] [Related]
17. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels.
Pollmächer T; Hinze-Selch D; Mullington J
J Clin Psychopharmacol; 1996 Oct; 16(5):403-9. PubMed ID: 8889915
[TBL] [Abstract][Full Text] [Related]
18. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
[TBL] [Abstract][Full Text] [Related]
19. Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Aguglia E; De Vanna M; Onor ML; Ferrara D
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1229-33. PubMed ID: 12502008
[TBL] [Abstract][Full Text] [Related]
20. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients.
Hinze-Selch D; Becker EW; Stein GM; Berg PA; Mullington J; Holsboer F; Pollmächer T
Neuropsychopharmacology; 1998 Aug; 19(2):114-22. PubMed ID: 9629565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
